18 Protein Arginine Methyltransferase (PRMT) 5 catalyzes symmetric dimethylation of arginine, a 19 post-translational modification involved in cancer and embryonic development. However, the 20 role of PRMT5 in T helper (Th) cell polarization and Th cell-mediated disease has not yet been 21 elucidated. Here we report that PRMT5 is necessary for Th17 differentiation and EAE, via 22 enhancement of cholesterol biosynthesis and activation of ROR-γt. PRMT5 additionally controls 23 thymic and peripheral homeostasis in the CD4 Th cell life cycle, as well as iNK T and CD8 T cell 24 development or maintenance, respectively. Overall, our two conditional PRMT5 KO models that 25 selectively delete PRMT5 in all T cells (T-PRMT5 ∆/∆ ) or Th cells (iCD4-PRMT5 ∆/∆ ) unveil a crucial 26 role for PRMT5 in T cell proliferation, Th17 responses and disease. These results point to Th 27 PRMT5 and its downstream cholesterol biosynthesis pathway as promising therapeutic targets 28 in Th17-mediated diseases. 29 30
Introduction 31
Arginine methylation is a post-translational modification of histones and other proteins that 32 regulates important physiological processes, including embryonic development and stem cell 33 biology. This modification is catalyzed by a group of ten Protein Arginine Methyl Transferase 34 (PRMT) enzymes (1) . Type I, II and III PRMTs catalyze asymmetric dimethylation (ADM), 35 symmetric dimethylation (SDM) and monomethylation of arginine (1), respectively. While both 36 PRMT5 and 9 can catalyze SDM, PRMT5 is considered responsible for the majority of SDM in the 37 cell (2). A short and a long isoform of this protein can be produced from the PRMT5 gene by 38 alternative splicing. PRMT5 overexpression is common during cellular transformation and 39 cancer. PRMT5 has been shown to methylate a number of targets, ranging from histones H4R3 40 and H3R8 to NF-κB and spliceosome proteins. PRMT5 thereby promotes cancer/stem cell 41 proliferation and survival (3). High proliferation and NF-κB signaling are also common in 42 immune cells such as B cells and T cells and PRMT5 has been shown to play an important role in 43 B cell biology (4). A crucial role for PRMT5 in T cell responses and immune disease is also just 44 beginning to be recognized. 45 46 We recently reported that PRMT5 undergoes induction after T cell activation in a process 47 controlled by NF-κB/MYC/mTOR signaling (5, 6). PRMT5's SDM mark has also been shown to be 48 dynamically regulated in T cells (7), suggesting it plays important functions. Indeed, we showed 49 that both PRMT5 inhibitors and sh-RNA genetic knockdown impair T cell proliferation (6) . 50
Subsequently, genetic deletion of one of the PRMT5 isoforms in all T cells recapitulated this 51 proliferation defect (8). However, it is not known how dual-isoform PRMT5 deletion impacts T 52 cell proliferation and differentiation of Th cells into Th1/Th2/Th17/Treg phenotypes of 53 importance in autoimmune and other diseases. Inflammatory Th1 and Th17 responses are 54 particularly pathogenic, as they drive chronic tissue damage in autoimmune diseases such as 55
Multiple Sclerosis (MS) (9). 56 57 Metabolic reprogramming upon T cell activation is a phenomenon that is increasingly 58 recognized as an essential part of regulating Th cell function and polarization. Activated T cells 59 grow and proliferate very rapidly, requiring the induction of a biosynthetic phenotype. Thus, 60 quiescent naive or resting memory T cells, which rely on oxidative phosphorylation and/or fatty 61 acid oxidation for energy generation, rapidly shift upon activation to biosynthetic metabolic 62 pathways including glycolysis and cholesterol biosynthesis. Inflammatory Th1 and Th17 cells, in 63 contrast to Tregs, require this highly glycolytic and biosynthetic reprogramming and cholesterol 64 biosynthesis is particularly important for Th17 cell differentiation (10). However, the driver/s 65 promoting the metabolic activation of the Th17 program is/are unknown. 66 67 Here we find that the arginine methyltransferase PRMT5 is required for Th17 differentiation via 68 enhancement of cholesterol biosynthesis and activation of ROR-γt. Consequently, PRMT5 69 expression in Th cells was required for the Th17-mediated disease EAE. PRMT5-catalyzed 70 methylation could influence multiple layers of the Th cell life cycle, from thymic development to 71 peripheral maintenance and Th differentiation. Indeed, we find that PRMT5 controls all three of 72 these processes, with strong impacts on CD4 Th cells at the thymic, peripheral homeostasis and 73 polarization cell stages. We also observe important defects in iNK T and CD8 T cell development 74 or maintenance, respectively, in the absence of PRMT5. Overall, our data unveil a crucial role 75 for PRMT5 in T cell proliferation, Th17 responses and disease and point to Th PRMT5 and its 76 downstream cholesterol biosynthesis pathway as promising therapeutic targets in Th17-77 mediated diseases. 78
Results 79

Development of constitutive pan-T cell-specific (T-PRMT5 ∆/∆ ) and inducible CD4 Th cell-80
specific (iCD4-PRMT5 ∆/∆ ) mouse models of PRMT5 deficiency. 81 PRMT5 is essential for embryonic development (11, 12) and hematopoietic cells development 82 (13). Therefore, evaluation of PRMT5's function in T cells requires conditional KO models that 83 allow PRMT5 deletion in a T cell subset-specific and time-controlled manner. To develop 84 conditional PRMT5 KO mice where both PRMT5 protein-coding isoforms ( Fig. 1A) are 85 specifically deleted in T cells, we used the Prmt5 tm2c(EUCOMM)wtsi mutation that flanks exon 7 with 86 loxP sites (13). To delete PRMT5 in all T cells (pan-T) or in the CD4 Th compartment, the 87 PRMT5 fl/fl mice were crossed to CD4-cre (14) or CD4-cre-ERT2 (15) mice, respectively. The CD4-88 cre transgene is constitutively expressed in all CD4 expressing cells, which would include the 89 thymic double positive T cells which would later develop into all CD3 + T cells, thereby providing 90 a mouse model in which all peripheral T cells lack PRMT5 ( Fig. 1B , T-PRMT5 ∆/∆ mice). In 91 contrast, the tamoxifen-inducible CD4-cre-ERT2 transgene majorly provides peripheral CD4 T 92 cell-specific deletion upon tamoxifen treatment ( Fig. 1B , iCD4-PRMT5 ∆/∆ mice) with a lesser 93 impact on DP thymocytes present during the tamoxifen treatment window (15). As expected, 94 the short PCR product corresponding to Prmt5 KO was amplified from both CD4 + Th and CD8 + 95
Tc cells in T-PRMT5 ∆/∆ mice (Fig. 1C) but only in CD4 + Th cells from tamoxifen-treated iCD4-96 PRMT5 ∆/∆ mice ( Fig. 1D) . 97 98 99 100
PRMT5 is necessary for normal thymic CD4 Th cell and regulatory T cell (Treg) development 101
We have previously shown that PRMT5 is essential for T cell proliferation (6). Since thymocyte 102 proliferation is a crucial event during T cell development, we evaluated the impact of PRMT5 103 deficiency on the thymic immune compartment by flow cytometry ( Fig. 2A) . Total thymic 104 numbers were slightly but not significantly reduced in T-PRMT5 ∆/∆ mice compared to PRMT5 fl/fl 105 and CD4-cre controls (Fig. 2B) . The CD4-cre driver is first expressed at the DP stage. As 106 expected, while total DN thymocyte numbers were unaffected (Fig. 2C) , a significant loss in the 107 DP compartment ( Fig. 2D ) was present. This defect was more prominent in the CD4SP (Fig. 2E ) 108
and Treg (Fig. 2F) populations. Interestingly, the loss of CD4SP cells was also observable in 109 heterozygous PRMT5 KO ( Fig. 2E) , indicative of PRMT5 haploinsufficiency during thymic CD4 T 110 cell development. In contrast, the CD8SP compartment was not significantly affected ( Fig. 2G) . 111
Consistent with the role of PRMT5 in proliferation, the observed thymic defects appear to be 112 due to reduced thymocyte expansion, as no significant impact on DN, DP or SP frequencies was 113 observed with the exception of reduced Treg frequency (Supplemental Fig 1) . 114
115
To evaluate the impact of PRMT5 deletion on peripheral immune populations, we analyzed 116 spleen and lymph nodes. While total splenocyte and lymph node cell numbers were unaffected 117
in T-PRMT5 ∆/∆ mice ( Fig. 2H and data not shown), flow cytometry analyses of T cell populations 118 ( Fig. 2I ) showed reduced numbers of CD4 Th cells and Tregs in the spleen ( Fig. 2J-K) and LNs 119 (data not shown), following the same pattern observed in the thymus. This suggests that CD4 T 120 cell defects could stem from thymic defects alone or, alternatively, combined thymic/peripheral 121 homeostasis defects. In contrast, thymic CD8 SP numbers were normal, but a robust loss of 122 CD8 + Tc cells was evident in T-PRMT5 ∆/∆ mice spleen ( Fig. 2L) and LNs (data not shown), 123
suggesting that CD8 T cell maintenance requires PRMT5. Among CD4 Th cells, all naive 124 (CD62L + CD44 -), effector memory (TEM, CD62L -CD44 + effector), and central memory (TCM, 125 CD62L + CD44 + ) CD4 + T cells were reduced ( Fig. 2M) . Within the CD8 T cell compartment, both 126 the naive, and TCM CD8 + T cells were drastically lost while no changes in TEM cells were observed 127 ( Fig. 2N) . Finally, as previously reported (8), we observed complete loss of iNKT cell populations 128 in both thymus and spleen of T-PRMT5 ∆/∆ mice ( Fig. 2O-Q) . Overall, these data show that 129 PRMT5 is required for thymic CD4 Th, Treg and iNK T cell development and normal CD4, CD8 130 and iNKT peripheral T cell compartments and that these defects are T cell intrinsic. 131
132
The observation that CD8 + T cell numbers were normal at the thymic level but robustly reduced 133 peripherally suggests that CD8 + T cells are highly dependent on PRMT5 in the periphery. The 134 peripheral CD4 + Th cell loss could result from thymic development defects or and/or peripheral 135 homeostasis defects. To address this, we took advantage of the iCD4-PRMT5 ∆/∆ model, which 136 allows temporally-controlled PRMT5 deletion, mostly impacting peripheral CD4 Th cells. To rule 137 out any effects on thymic development, we evaluated thymocytes and peripheral immune cell 138 compartments in adult iCD4-PRMT5 ∆/∆ mice (Supplemental Fig. 2A ). As expected, thymic 139 compartments were unaffected in iCD4PRMT5 ∆/∆ mice after 1 week of tamoxifen treatment 140 . 3J ). We confirmed that this model is selective for 147 CD4 + T cells, as CD8 + Tc populations were unaffected with extended tamoxifen treatment 148 (Supplemental Fig. 3F, I) . In summary, these data demonstrate that PRMT5 expression 149 promotes both thymic T cell development and peripheral CD4 and CD8 T cell maintenance. 150
151
PRMT5 drives CD4 + Th cell proliferation. 152
To evaluate the impact of PRMT5 deficiency on peripheral Th cell function, we isolated CD4 + Th 153 cells from T-PRMT5 ∆/∆ and analyzed them 48 hours after TcR engagement. We confirmed the 154 near complete loss of PRMT5 protein expression in T-PRMT5 ∆/∆ Th cells compared to controls 155 ( Fig. 3A, B) . The type I methyltransferase PRMT1 was also slightly reduced ( Fig. 3A, C) , 156 confirming previously reported positive modulation of PRMT1 by PRMT5 (6). Functionally, such 157 PRMT5 loss resulted in a robust (≥ 80%) suppression of proliferation in both CD4 Th cells ( Fig.  158 Fig. 4 ). To determine whether the proliferative defect 159 is also present in T cells deleted of PRMT5 after thymic development, we analyzed Th cells from 160 iCD4PRMT5 ∆/∆ mice. We found that PRMT5 protein induction after TcR-stimulation was 161 suppressed to a lesser extent in this model, approximately 60-70% ( Fig. 3E, F) , consistent with 162 the lower efficiency of the iCD4-cre-ER driver (15). PRMT1 maintained normal expression ( Fig.  163 3E, G). In this model, Th cell proliferation was again suppressed (Fig. 3H) . These data 164 conclusively demonstrate a driver role for PRMT5 in TcR-induced CD4 Th and CD8 Tc cell 165 proliferation. 166
3D) and total CD3 + T cells (Supplemental
PRMT5 regulates Th cell differentiation. 167
Naive Th cell activation leads to differentiation into various Th cell phenotypes depending on 168 the environmental milieu. Inflammatory Th1 and Th17 responses are highly pathogenic and 169 drive chronic tissue damage in the autoimmune disease of the central nervous system MS (9). 170
We first evaluated the impact of PRMT5 on Th cell differentiation in the T-PRMT5 ∆/∆ model 171 where T cells lose PRMT5 during thymic development ( Fig. 4A) . Surprisingly, we observed 172 increased Th1 differentiation among live CD44 + cells, following a slight defect in IFN-γ-secreting 173 Th1 cells at day 3 (see with PRMT5 deficiency in this model, with the exception of reduced IFN-γ secretion at day 3, a 181 defect recovered by day 7 (Fig. 4K-N) . Likewise, Th17 polarization was practically absent, with 182 lack of IL-17 secretion and RORγt induction ( Fig. 4O-R) . Overall, these data indicate that PRMT5 183 suppresses Th1 differentiation but is essential for Th17 differentiation. . 5A ). Total CNS infiltrating T cell numbers 220 were robustly reduced in iCD4-PRMT5 ∆/∆ mice (Fig. 6C) , even as normal T cell numbers exist in 221 the periphery (Supplemental Fig. 2T-Y) . Within CD4 Th cells, important losses were evident in 222 the CD44 + CD62L -TEM and CD44 + CD62L + TCM Th cells compartments ( Fig. 6D-E) . This indicates 223 that Th-specific PRMT5 deficiency in Th cells is sufficient to impair recruitment of memory Th 224 cells, presumably with pathogenic phenotypes, into the CNS. To address this, myelin-specific T 225 cell proliferation and pathogenic Th1 and Th17 responses were evaluated in the CNS. 226
Infiltrating CNS cells from iCD4-PRMT5 ∆/∆ mice did not proliferate (Fig. 6F) or secrete IFNγ (Fig.  227 6G) or IL-17 ( Fig. 6H) in response to MOG. In particular, a substantial loss of MOG-specific 228 Tbet + IFNγ + Th1 cells (Fig. 6I) , RORγt + IL-17 + Th17 cells (Fig. 6J) , and the particularly pathogenic 229 Tbet + IL-17 + Th17 population (Fig. 6K) was observed. 230 231 Since Th17 differentiation is abrogated in the absence of PRMT5, we expected this defect to be 232 evident in peripheral T cell responses in the spleen. MOG-specific T cell proliferation (Fig. 6L) , 233 Th1 (Fig. 6M, O) and Th17 (Fig. 6N, P) responses, including the highly pathogenic Tbet + IL-17 + 234
Th17 cells (Fig. 6Q) Alternatively, it may be mediated by the ubiquitous Prmt5 heterozygous deficient background 263 used in that model (8). The second possibility is highly likely, as we observed thymic defects in 264 both PRMT5 homozygous and heterozygote mice in comparison to both PRMT5 fl/fl and CD4-cre 265 controls (Fig. 2) . While DP and CD4 SP numbers were decreased, their relative distribution 266 remained stable, suggesting a defect mediated by impaired expansion. In contrast, CD8 SP 267 numbers were normal, consistent with the higher proliferation that DP and CD4 SP cells vs. CD8 268 SP undergo during thymic development (28). Finally, as in the previous report (8) (30-34). The driver role of PRMT5 in cancer has led to efforts to develop PRMT5 selective 286 inhibitors as a therapy for solid and hematologic cancers, currently being tested for safety and 287 efficacy (Clinicaltrials.gov, registration ID: NCT03573310, NCT03854227, NCT02783300, 288 NCT03614728). Homozygous, but not heterozygote, PRMT5 deficiency early in bone marrow 289 hematopoiesis results in severe bone marrow aplasia and eventual death (13). This phenotype 290 has informed safety evaluation studies during clinical trials. We now show that complete 291 PRMT5 deletion plays crucial roles in T cell development and biology, with robust suppression 292 of Th17 and Th1 responses generally involved in pathogen protective immunity. It is important 293 to note that more subtle or absent immune effects were observed in heterozygote Th PRMT5 294 KO mice, suggesting that careful PRMT5 inhibitor dosing could be the key to avoiding 295 unintended effects. Such considerations will also be important when considering PRMT5 296 inhibitors for T cell-mediated diseases, albeit many of the T cell effects we here describe may 297 instead serve a therapeutic role. Overall, it will be important to carefully monitor potential 298 immune effects in PRMT5 inhibitor-based therapeutic approaches. drives Th17 cell differentiation by promoting cholesterol biosynthesis. It is important to note 308 that PRMT5 promotes cholesterol biosynthesis enzyme expression even in the absence of Th17-309 inducing cytokines ( Fig. 5A-C) . This is consistent with the idea that PRMT5 expression at the Th0 310 stage pushes Th17 differentiation via production of ROR-γt agonistic cholesterol pathway 311 intermediates. These findings fit with observations in statin-treated Multiple Sclerosis patients. 312
Statin drugs inhibit the HMG-CoA reductase rate-limiting step in the cholesterol biosynthesis 313 pathway (37) and substantially reduce disability scores and atrophy in MS patients (38, 39) . It 314
has been unclear what is the mechanism behind these effects, but causal modeling analyses 315 suggest an effect independent of peripheral cholesterol levels (40). Instead, these analyses We found that PRMT5 expression in peripheral CD4 + T cells is an essential driver for the 322 development of EAE disease. While pan-T cell T-PRMT5 ∆/∆ mice were completely resistant to 323 EAE, this effect could be due to these mice lacking a full CD4, CD8 and iNK T cell compartments. 324
Using the inducible peripheral CD4 Th-cell specific PRMT5 KO model (iCD4-PRMT5 ∆/∆ ), we 325 confirmed that PRMT5 in CD4 + Th cells is required for EAE development. We observed strongly 326 reduced proliferative, Th17 and Th1 recall responses in these mice, as well as severely reduced 327 numbers of memory T cell infiltration in the CNS. The loss of Th17 responses was consistent 328 with reduced Th17 differentiation. However, the Th1 cell response was also lost during EAE, in 329 apparent contradiction to increased Th1 polarization observed ( Fig. 4B-E, K-N An initial denaturation step at 95•C for 10 min was followed by 40 cycles of denaturation at 438 95•C for 15 s and primer annealing/extension at 60•C for 60 s. Results were analysed using the 439 comparative Ct method after ensuring comparable amplification efficiencies for test and 440 housekeeping transcripts. 441
Experimental autoimmune encephalomyelitis. To induce EAE, mice were immunized with myelin 442 oligodendrocyte glycoprotein peptide (MOG35-55; CS Bio) and CFA (Difco) emulsion, as 443 previously described (6). Mice were monitored for disease every day and scored blinded. At the 444 indicated time points, mice were euthanized by injection with 20 mg/ml ketamine and 4 mg/ml 445 xylazine (150 µl/20 g mouse) and perfused with PBS. Spleens, brains, and spinal cords were 446 collected from representative mice and processed for in vitro studies. To isolate brain and 447 spinal cord mononuclear cells, brains and spinal cords were processed through a 70-µm strainer 448 and separated by a 70-30% isotonic Percoll gradient. Spleens were processed through a 70-µm 449 strainer and red blood cells were lysed by incubating for 1 minute in hypotonic solution. 450
Splenocytes and infiltrating CNS cells were used for ex vivo flow cytometry or reactivated with 451 MOG antigen as indicated. 452
Statistical analysis. Statistical analyses were performed using GraphPad Prism unless otherwise 453 stated. One-way ANOVA and Student's t tests were used as appropriate, and as indicated. 
